Page 1215 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1201

Cigarette smoking, 120 phase 1, 16 Cobalt, 1017
Cilastatin, 807 phase 2, 16 Cobimetinib, 975
Cilostazol phase 3, 17 Cocaine, 143f, 372, 460t, 470, 472t.
description of, 209, 621 phase 4, 17 See also Anesthetics, local
peripheral artery disease and intermittent randomized controlled trails, 15b abuse of, 577t, 581
claudication treated with, 209 Clobazam, 430, 432, 433t, 437t biogenic amine binding in, 585–586,
Cimetidine, 1089. See also H 2 -receptor CLOCK/BMAL-1, 706 586f
antagonists Clofazimine, 843t, 851 clinical uses of, 151
description of, 71, 296t, 1089–1091 Clomiphene, 737f, 738, 739–740 on dopamine transporter, 586, 586f
drug interactions of, 1163t Clomipramine, 540t, 542t, 546t historical development of, 461b
Cinacalcet Clonazepam, 393t. See also Benzodiazepines on NET, 95
on bone homeostasis, 781 restless legs syndrome treated with, 507 Coccidioides immitis, 862
hyperparathyroidism treated with, 784, seizures treated with, 432, 433t, 437t Cockcroft-Gault formula, 1060
790t Clonidine. See also Sympathomimetics Codeine, 77, 568, 572t. See also Opioid
Cinchonism, 924 description of, 149, 154t, 191t agonists
Cinryze, 308, 317t. See also Kinin hypertension treated with, 179t, antitussive, 570, 572t
inhibitors 179–181 CYP2D6 activity on metabolism of,
Ciprofloxacin, 838–839 tics treated with, 506, 508t 77–80, 79t
Circumventricular organs, 369 withdrawal syndrome, 184 G io protein-coupled receptor activation
Cirrhosis, 271 Clonorchiasis, 944 by, 581, 583f
Cisapride, 291, 1163t–1164t Clopidogrel properties of, 555t
Cisatracurium. See also Neuromuscular antiplatelet effects of, 620 Coding single nucleotide polymorphisms
blocking drugs CYP2C19 on metabolism of, 78, 79t (cSNPs), 75, 75t
pharmacokinetics of, 477 peripheral artery disease and intermittent Coenzyme Q10, 1141–1142
properties of, 478t, 489t claudication treated with, 209 Cohort epidemiologic studies, 15b
Cisplatin, 955t, 956–957 Clorazepate, 383, 385t, 393t, 432. See also Colchicine, 1164t
Citalopram, 549t. See also Selective serotonin Benzodiazepines Cold-induced urticaria, 292
reuptake inhibitors (SSRIs) Clostridium difficile, 895, 903 Cold medications, hypertension from,
blocking effects of, 542t Clotrimazole, topical, 860 1120, 1130
dosing of, 546t dermatologic, 1072 Colesevelam hydrochloride, 636–637, 640t
pharmacokinetics of, 540t Clotting factors, 610t, 610–611, 611f diabetes mellitus treated with, 764, 769t
poisoning with, 1042 Clotting prevention agents, 624t diarrhea treated with, 1100
Cladribine, 958t, 961 Clozapine, 514f, 515, 520t, 529t Colestipol
Clarithromycin, 819f, 820, 824t Club drugs, 587 description of, 636–637, 640t
Classic angina, 194 Coagulation diarrhea treated with, 1100
Claudication, intermittent, 209, 211t estrogens on, 725 Collecting tubule system, 255f, 257–259,
Clavulanic acid, 806f, 806–807 mechanisms of, 608–609 258f
Clearance (CL), 42–46. See also specific Coagulation cascade, 609–611, 610f Colloidal bismuth compounds, 1100
drugs fibrinolysis in, 611, 611f Colonic pseudo-obstruction, acute, 1097
capacity-limited elimination in, 45–46 fundamentals of, 608, 610t, 611f Colony-stimulating factors, 600
for drug concentration measurement tissue factor-VIIa complex in, 610–611, Colorectal cancer
interpretation, 53 611f case study of, 948, 976
flow-dependent elimination in, 46 Coagulation disorder drugs, 608–625 dihydropyrimidine dehydrogenase
initial predictions of, 54 anticoagulants, 611–618, 624t enzyme deficiency on, 976
rate of elimination in, 45 antiplatelet agents, 619–620, 624t Coltsfoot, 1133t
revising individual estimates of, 54 aspirin, 619–620 Combined toxicity, of drug interactions,
on target concentration, 52 cilostazol, 621 1173
total systemic, 45 dipyridamole, 621 Comfrey, 1133t
Clevidipine, 187 GP IIb/IIIa antagonists, 621 Commensal gut microbiota, 69–70
Clindamycin, 821–822, 824t thienopyridines, 620 Community-acquired pneumonia,
acne treated with, 1071 antithrombotics, 624t cephalosporin and vancomycin
malaria treated with, 928 factor VIIa, recombinant, 622t, 623, for, 795, 814
Clinical Pharmacogenetics Implementation 624t Competitive antagonists, 23f, 23–24
Consortium (CPIC), 74 fibrinolytic inhibitors, 622t, 623, 624t Competitive inhibitor, 5, 6f
Clinical trials, 15–17 fibrinolytics, 611f, 618–619, 624t Complementary medicine, 3
confounding factors in, 14 plasma fractions, 621–623, 622t, 624t Compliance (adherence), 1150–1151
controlled, 2 vitamin K for bleeding disorders, 614f, Compound 21, 305, 316t
IND & NDA, 12f, 15–17 621, 622t Compound 48/80, 278, 280